---
document_datetime: 2025-09-25 09:47:42
document_pages: 40
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-public-assessment-report_en.pdf
document_name: emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-public-assessment-report_en.pdf
version: success
processing_time: 30.8714954
conversion_datetime: 2025-12-29 23:02:01.85585
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

19 June 2025 EMA/CHMP/200896/2025 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

etricitabine/rilpivirine/tenofovir alafenamide Viatris

International non-proprietary name: emtricitabine / rilpivirine / tenofovir alafenamide

Procedure No. EMEA/H/C/006491/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                   | ..............................................4                                                          |
|------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................4        |                                                                                                          |
| 1.2. Legal basis, dossier content...................................................................................4        |                                                                                                          |
| 1.3. Information on paediatric requirements...................................................................5              |                                                                                                          |
| 1.4. Information relating to orphan market exclusivity.....................................................5                 |                                                                                                          |
| 1.4.1. Similarity..........................................................................................................5 |                                                                                                          |
| 1.5. Scientific advice                                                                                                       | ...................................................................................................5     |
| 1.6. Steps taken for the assessment of the product.........................................................5                 |                                                                                                          |
| 2. Scientific discussion                                                                                                     | ................................................................................6                        |
| 2.1. Quality aspects                                                                                                         | ....................................................................................................6    |
| 2.1.1. Introduction......................................................................................................6   |                                                                                                          |
| 2.1.2. Emtricitabine active substance                                                                                        | ............................................................................7                            |
| 2.1.3. Rilpivirine active substance.................................................................................9        |                                                                                                          |
| 2.1.4. Tenofovir alafenamide fumarate active substance................................................11                     |                                                                                                          |
| 2.1.5. Finished medicinal product................................................................................13          |                                                                                                          |
| 2.1.6. Discussion on chemical, and pharmaceutical aspects............................................15                      |                                                                                                          |
| 2.1.7. Conclusions on the chemical, pharmaceutical and biological aspects                                                    | ......................16                                                                                 |
| 2.1.8. Recommendations for future quality development................................................16                      |                                                                                                          |
| 2.2. Non-clinical aspects                                                                                                    | ............................................................................................16           |
| 2.2.1. Introduction....................................................................................................16    |                                                                                                          |
| 2.2.2. Ecotoxicity/environmental risk assessment                                                                             | .........................................................16                                              |
| 2.2.3. Discussion on non-clinical aspects......................................................................17            |                                                                                                          |
| 2.2.4. Conclusion on the non-clinical aspects................................................................17              |                                                                                                          |
| 2.3. Clinical aspects                                                                                                        | ..................................................................................................18     |
| 2.3.1. Exemption                                                                                                             | ......................................................................................................18 |
| 2.3.2. Clinical pharmacology                                                                                                 | ......................................................................................19                 |
| 2.3.3. Discussion on clinical pharmacology ............................................................35                    |                                                                                                          |
| 2.3.4. Conclusions on clinical aspects                                                                                       | ..........................................................................37                             |
| 2.4. Risk Management Plan                                                                                                    | ........................................................................................37               |
| 2.4.1. Safety concerns...............................................................................................37      |                                                                                                          |
| 2.4.2. Pharmacovigilance plan                                                                                                | ....................................................................................37                   |
| 2.4.3. Risk minimisation measures..............................................................................38            |                                                                                                          |
| 2.4.4. Conclusion......................................................................................................38    |                                                                                                          |
| 2.5. Pharmacovigilance..............................................................................................38       |                                                                                                          |
| 2.5.1. Pharmacovigilance system................................................................................38            |                                                                                                          |
| 2.5.2. Periodic Safety Update Reports submission requirements                                                                | .....................................38                                                                  |
| 2.6. Product information                                                                                                     | ............................................................................................39           |
| 2.6.1. User consultation.............................................................................................39      |                                                                                                          |
| 3. Benefit-risk balance ..............................................................................39                     |                                                                                                          |
| 4. Recommendations.................................................................................40                        |                                                                                                          |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AE/s

Adverse event/s

AIDS

Acquired immune deficiency syndrome

ALT

Alanine aminotransferase

ANOVA

Analysis of variance

ASMF

Active substance master file

AST

Aspartate aminotransferase

ATC

Anatomical therapeutic chemical

AUCtau

Area under plasma concentration-time curve over dosing interval

BCRP

Breast cancer resistance protein

BCS

Biopharmaceutics classification system

BMD

Bone mineral density

Cmax

Peak plasma concentration

Cmin

Minimum plasma concentration

CI

Confidence interval

EC

European Commission

EU

European Union

GC

Gas chromatography

GC-MS

Gas chromatography mass spectrometry

GC-MS/MS

Gas chromatography mass spectrometry/mass spectrometry

GMP

Good manufacturing practice

HDPE

High density polyethylene

HIV-1

Human immunodeficiency virus-1

HPLC

High performance liquid chromatography

ICH

International Council for Harmonisation of Technical Requirements for Pharmaceuticals

for Human Use

IR

Infrared

KF

Karl Fischer titration

LC-MS/MS

Liquid chromatography-tandem mass spectroscopy

LDPE

Low density polyethylene

LOQ

Limit of quantification

MO

Major objection

NMR

Nuclear magnetic resonance

NMT

Not more than

OOS

Out of specification

OPA

Oriented polyamide

PE

Polyethylene

Ph. Eur.

European Pharmacopoeia

PI

Principal investigator

PK

Pharmacokinetic

PP

Polypropylene

PXRD

X-ray powder diffraction

PVC

Polyvinyl chloride

PVDC

Polyvinylidene chloride

QC

Quality control

QP

Qualified person

QTPP

Quality target product profile

(Q)SAR

(Qualitative) structure activity relationship

RH

Relative humidity

rpm

Revolutions per minute

SAE/s

Serious adverse event/s

SmPC

Summary of product characteristics

TSE

Transmissible spongiform encephalopathy

UV

Ultraviolet

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Viatris Limited submitted on 25 June 2024 an application for marketing authorisation to the European Medicines Agency (EMA) for Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004- 'Generic of a Centrally authorised product'. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 25 January 2024.

The application concerns a generic medicinal product as defined in Article 10(2)(b) of Directive 2001/83/EC and refers to a reference product, as defined in Article 10 (2)(a) of Directive 2001/83/EC, for which a marketing authorisation is or has been granted in the Union on the basis of a complete dossier in accordance with Article 8(3) of Directive 2001/83/EC.

The applicant applied for the following indication:

Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated with resistance to the nonnucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤ 100 000 HIV-1 RNA copies/mL (see sections 4.2, 4.4 and 5.1).

## 1.2. Legal basis, dossier content

## The legal basis for this application refers to:

Generic application (Article 10(1) of Directive No 2001/83/EC).

The application submitted is composed of administrative information, complete quality data and a bioequivalence study with the reference medicinal product Odefsey instead of non-clinical and clinical unless justified otherwise.

The chosen reference product is:

Medicinal product which is or has been authorised in accordance with Union provisions in force for not less than 8 years in the EEA:

- Product name, strength, pharmaceutical form: Odefsey, Film-coated tablet, 200 mg/25 mg/25 mg
- Marketing authorisation holder: Gilead Sciences Ireland UC
- Date of authorisation: 21-06-2016
- Marketing authorisation granted by:
- -Union
- Union Marketing authorisation number: EU/1/16/1112

Medicinal product authorised in the Union/Members State where the application is made or European reference medicinal product:

- Product name, strength, pharmaceutical form: Odefsey, Film-coated tablet, 200 mg/25 mg/25 mg
- Marketing authorisation holder: Gilead Sciences Ireland UC
- Date of authorisation: 21-06-2016

<div style=\"page-break-after: always\"></div>

- Marketing authorisation granted by:
- -Union
- Marketing authorisation number: EU/1/16/1112

Medicinal product which is or has been authorised in accordance with Union provisions in force and to which bioequivalence has been demonstrated by appropriate bioavailability studies:

- Product name, strength, pharmaceutical form: Odefsey, Film-coated tablet, 200 mg/25 mg/25 mg
- Marketing authorisation holder: Gilead Sciences Ireland UC
- Date of authorisation: 21-06-2016
- Marketing authorisation granted by:
- -Union
- Marketing authorisation number(s): EU/1/16/1112/001, EU/1/16/1112/002
- Bioavailability study number(s): EMRTA-TFZ-1003

## 1.3. Information on paediatric requirements

Not applicable

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## 1.5. Scientific advice

The applicant did not seek scientific advice from the CHMP.

## 1.6. Steps taken for the assessment of the product

The Rapporteur appointed by the CHMP was:

Rapporteur:

Ewa Balkowiec Iskra

| The application was received by the EMA on                                                   | 25 June 2024   |
|----------------------------------------------------------------------------------------------|----------------|
| The procedure started on                                                                     | 18 July 2024   |
| The CHMP Rapporteur's first assessment report was circulated to all CHMP and PRAC members on | 2 October 2024 |
| The PRAC Rapporteur's first assessment report was circulated to all                          | 2 October 2024 |

<div style=\"page-break-after: always\"></div>

| PRAC and CHMP members on                                                                                                                                                                                                                |                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The CHMP agreed on the consolidated list of questions to be sent to the applicant during the meeting on                                                                                                                                 | 14 November 2024 |
| The applicant submitted the responses to the CHMP consolidated list of questions on                                                                                                                                                     | 21 February 2025 |
| The CHMP Rapporteur circulated the CHMP and PRAC Rapporteurs joint assessment report on the applicant's responses to the list of questions to all CHMP members on                                                                       | 25 March 2025    |
| The PRAC agreed on the PRAC assessment overview and advice to CHMP during the meeting on                                                                                                                                                | 10 April 2025    |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                                                                 | 25 April 2025    |
| The applicant submitted the responses to the CHMP consolidated list of outstanding issues on                                                                                                                                            | 20 May 2025      |
| The CHMP Rapporteur circulated the CHMP and PRAC Rapporteurs joint assessment report on the responses to the list of outstanding issues to all CHMP and PRAC members on                                                                 | 2 June 2025      |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris on | 19 June 2025     |

## 2. Scientific discussion

## 2.1. Quality aspects

## 2.1.1. Introduction

The finished product is presented as immediate release, film-coated tablets containing emtricitabine, rilpivirine and tenofovir alafenamide 200 mg/25 mg/25 mg as active substances. Tenofovir alafenamide is present as the monofumarate salt and rilpivirine is present as the hydrochloride salt.

Other ingredients are:

Tablet cores: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, povidone (K-30), maize starch, and lactose monohydrate.

Film-coating: polyvinyl alcohol, calcium carbonate, macrogol (MW 3350) and talc.

The product is available in OPA/aluminium/PE+desiccant+HDPE Coating - aluminium/PE blister packs or HDPE bottles with white opaque PP child-resistant closures with aluminium induction sealing liner wads along with desiccant.

<div style=\"page-break-after: always\"></div>

## 2.1.2. Emtricitabine active substance

## 2.1.2.1. General information

The chemical name of emtricitabine is 4-amino-5-fluoro-1-[(2 R ,5 S )-2-(hydroxymethyl)-1,3-oxathiolan5-yl]-2(1 H )-pyrimidinone  corresponding  to  the  molecular  formula  C8H10FN3O3S.  It  has  a  relative molecular mass of 247.25 g/mol and the following structure:

## Figure 1. Emtricitabine structure

<!-- image -->

The chemical structure of emtricitabine was elucidated by a combination of IR, UV,  1 H NMR and  13 C NMR spectroscopy, mass spectrometry, elemental analysis and x-ray powder diffraction (PXRD).

Emtricitabine is a white to off-white powder, freely soluble in aqueous media from pH 1.2-8. The active substance is non-hygroscopic.

Emtricitabine exhibits stereoisomerism due to the presence of two chiral centres. Enantiomeric purity is controlled routinely in the active substance by chiral HPLC.

Polymorphism has been observed for emtricitabine and various polymorphic forms exist.  The drug substance manufacturer consistently produces single polymorphic form of Emtricitabine which is controlled routinely in the active substance by PXRD.

## 2.1.2.2. Manufacture, characterisation and process controls

Detailed information on the manufacturing of the active substance has been provided in the restricted part of the ASMF and it was considered satisfactory.

The active substance is manufactured by three manufacturers. Satisfactory GMP documentation of the sites has been provided.

Emtricitabine is synthesised in several steps using well defined starting materials with acceptable specifications. The route of synthesis of the intermediate from the two proposed manufacturers is similar, differing only in the choice of reagents and solvents as highlighted in red boxes in the scheme. Batch data of emtricitabine manufactured with both sources of the intermediate was provided. All tested parameters were within the specification limits and the quality of intermediate and the resultant active substance from sources is considered equivalent.

Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented. The proposed starting

<div style=\"page-break-after: always\"></div>

materials have been appropriately justified according to ICH Q11, and their specifications are acceptable.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of active substances. Potential and actual impurities were well discussed with regards to their origin and characterised. Risk assessments for genotoxic, solvent, elemental and nitrosamine impurities were provided. The risk assessments and applied control measures are considered appropriate.

The active substance packaging has been clearly described and is acceptable, complying with EC 10/2011 as amended.

## 2.1.2.3. Specification

The active substance specification followed by the finished product manufacturer includes tests for: appearance (visual), solubility (Ph. Eur.), identity (IR, HPLC, PXRD), melting point (Ph. Eur.), specific optical rotation (Ph. Eur.), loss on drying (Ph. Eur.), sulphated ash (Ph. Eur.), related substances (HPLC), enantiomeric impurity (chiral HPLC), assay (HPLC), residual solvents (GC), particle size (laser diffraction), and other solvent and reagent-related impurities (GC-HS, GC-MS/MS).

Impurities present at higher than the qualification threshold according to ICH Q3A were qualified by toxicological and clinical studies and appropriate specifications have been set.

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards was presented.

Batch analysis data from five production scale batches of the active substance were provided. The results were within the specifications and consistent from batch to batch.

## 2.1.2.4. Stability

Stability data to support the requested re-test period and storage condition is provided.

Stability data from three production scale batches of active substance from the proposed manufacturer, stored in the intended commercial package for up to 18 months under long term conditions (25ºC / 60% RH) and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided. Photostability testing following ICH guideline Q1B was performed on one batch.

The following parameters were tested : description, identification, melting range, specific optical rotation, loss on drying, enantiomer content, related substances, and assay. The analytical methods used were the same as for release and are stability indicating as demonstrated during forced degradation studies. All tested parameters were within the specifications and no significant trends were observed. Emtricitabine is photostable.

The stability results indicate that the active substance manufactured by the proposed supplier is sufficiently stable. The overall of stability results justify the proposed retest period in the proposed container.

<div style=\"page-break-after: always\"></div>

## 2.1.3. Rilpivirine active substance

## 2.1.3.1. General information

The chemical name of rilpivirine hydrochloride is 4-{[4-({4-[( E )-2-cyanoethenyl]-2, 6-dimethylphenyl} amino) pyrimidin-2-yl] amino} benzonitrile hydrochloride corresponding to the molecular formula C22H18N6.HCl. It has a relative molecular mass of 402.88 g/mol and the following structure:

## Figure 2. Active substance structure

<!-- image -->

The chemical structure of rilpivirine hydrochloride was elucidated by a combination of IR spectroscopy, UV spectroscopy,  1 H and  13 C NMR spectroscopy, mass spectrometry and elemental analysis. The solidstate properties were measured by x-ray powder diffraction (PXRD).

Rilpivirine hydrochloride is a non-hygroscopic, off white to yellow coloured crystalline powder, practically insoluble in aqueous media over the physiological pH range.

Rilpivirine hydrochloride does not contain a chiral centre but does have two potential geometric isomers of the cyanoethenyl double bond. The proposed active substance manufacturer produces the ( E )-isomer.

Polymorphism has been observed, and the drug substance manufacturer consistently produces same polymorphic form for rilpivirine hydrochloride.

## 2.1.3.2. Manufacture, characterisation and process controls

Detailed information on the manufacturing of the active substance has been provided in the restricted part of the ASMF.

Rilpivirine hydrochloride is manufactured by two manufacturers. The GMP compliance of the sites has been confirmed via relevant QP declaration.

The process consists of several synthetic steps followed by purification and salt formation. The starting materials are suitably defined, and their specifications are acceptable. During the procedure a major objection (MO) was raised on the initially proposed starting materials. In response the applicant redefined the proposed starting material(s) to an earlier step in the synthesis, and the MO was considered resolved. Details of the assessment are provided in the restricted part of the ASMF.

Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented. The characterisation

<div style=\"page-break-after: always\"></div>

of the active substance and its impurities are in accordance with the EU guideline on chemistry of active substances. Potential and actual impurities were well discussed with regards to their origin and characterised. The development of the manufacturing process was adequately described.

The active substance packaging has been clearly described and is acceptable, complying with EC 10/2011 as amended.

## 2.1.3.3. Specification

The active substance specification includes tests for: appearance, identity (IR, HPLC, test for chloride), assay (HPLC), related substances (HPLC), residual solvents (GC), water content (KF), sulphated ash (Ph. Eur.), acetic acid content (HPLC), polymorphic identity (PXRD) and particle size distribution (laser diffraction).

Rilpivirine hydrochloride is not described in Ph. Eur. The in-house specification is based on the batch analysis data and complies with compendial general tests and ICH guidance. The proposed specification is considered suitable to control the quality of the active substance.

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. The assay and related substances HPLC methods are demonstrated to be stability indicating through stressed stability studies. Peak purity and mass balance have been demonstrated. Satisfactory information regarding the reference standards has been presented. The finished product manufacturer's specification and analytical methods for rilpivirine hydrochloride are the same as those employed by the ASMF holder with the addition of a test and method for particle size.

Batch analysis data from three production batches of the active substance were provided. The results were within the specifications and consistent from batch to batch.

## 2.1.3.4. Stability

Stability data from three production scale batches of active substance from the proposed manufacturer stored in a container closure system representative of that intended for the market for up to 60 months under long term conditions (25ºC / 60% RH) and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided.

The following parameters were tested : appearance, identity (IR), assay, impurities, water content, and polymorphic identity (PXRD). All tested parameters were within the specifications.

The analytical methods used were the mostly same as for release and are stability indicating. A new HPLC impurities method was used at the 60-month timepoint, whereas data at earlier timepoints was generated with a different HPLC method. Suitable validation data for the old and new HPLC impurities methods was provided.

Photostability testing following ICH Q1B was performed as part of the forced degradation studies. Results indicated that rilpivirine hydrochloride is not sensitive to light.

The stability results indicate that the active substance manufactured by the proposed manufacturer is sufficiently stable. The stability results justify the proposed retest period and storage conditions.

<div style=\"page-break-after: always\"></div>

## 2.1.4. Tenofovir alafenamide fumarate active substance

## 2.1.4.1. General information

The chemical name of tenofovir alafenamide monofumarate is propan-2-yl N -[( S )-({[2 R )-1-(6-amino9H-purin-9-yl)propan-2-yl]-oxy}methyl)(phenoxy)phosphoryl]-L-alaninate, (2 E )-but-2-enedioate (1:1) corresponding to the molecular formula C21H29N6O5P.C4H4O4. It has a relative molecular mass of 592.55 g/mol and the following structure:

## Figure 3. Tenofovir alafenamide monofumarate structure

<!-- image -->

The chemical structure of tenofovir alafenamide monofumarate was elucidated by a combination of IR, UV,  1 H and  13 C NMR spectroscopy, mass spectrometry and elemental analysis. The solid-state properties of the active substance were measured by PXRD.

Tenofovir alafenamide monofumarate is a white to off-white or light tan coloured non-hygroscopic powder. The active substance is sparingly soluble in aqueous media across the pH range 1.2-8.0.

Tenofovir alafenamide monofumarate exhibits stereoisomerism due to the presence of three chiral centres. The control strategy has been appropriately justified and includes limits for the relevant impurities in the active substance specification.

Polymorphism has been observed for active substance. The present process consistently produces the same crystalline which is routinely controlled in the active substance specification. The stability of the polymorphic form throughout the shelf-life of the active substance was demonstrated.

## 2.1.4.2. Manufacture, characterisation and process controls

The active substance is manufactured by two manufacturers. The GMP compliance of the sites has been confirmed via relevant QP declaration.

Detailed information on the manufacturing of the active substance has been provided in the restricted part of the ASMF and it was considered satisfactory.

Tenofovir alafenamide monofumarate is synthesised in several steps using well defined starting materials, justified according to ICH Q11, with acceptable specifications.

Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented. The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin and characterised. Risk assessments for genotoxic, solvent, elemental and nitrosamine impurities were provided. No risk of nitrosamines impurities or elemental impurities was identified; solvents are controlled according to ICH Q3C.

<div style=\"page-break-after: always\"></div>

The risk assessment for potentially genotoxic impurities in the initial submission was not considered adequate as the hazard assessment was not conducted according to ICH M7, and impurities with structural alerts present in the starting materials had not been considered, resulting in a major objection (MO). In response, the applicant provided an updated risk assessment, classifying mutagenic impurities according to ICH M7 and providing (Q)SAR results and bacterial reverse mutagenicity assay results as appropriate. All mutagenic impurities are controlled according to ICH M7 option 4 and data has been provided as justification. The MO was thus resolved.

The active substance packaging has been clearly described and is acceptable, complying with EC 10/2011 as amended.

## 2.1.4.3. Specification

The active substance specification applied by the finished product manufacturer includes tests for appearance (visual), solubility (Ph. Eur.), identification (IR, HPLC, PXRD), water content (KF), sulfated ash (Ph. Eur.), chiral purity (chiral HPLC), related substances (HPLC), fumaric acid content (HPLC), assay (HPLC), residual solvents (GC-HS), and particle size (laser diffraction).

Tests included in the specification for the active substance are in line with requirements of ICH Q6A and are considered acceptable. Impurities present at higher than the qualification threshold according to ICH Q3A were qualified by toxicological and clinical studies and appropriate specifications have been set.

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards has been presented.

Batch analysis data from three production scale batches of the active substance were provided. The results were within the specifications and consistent from batch to batch.

## 2.1.4.4. Stability

Stability data from three commercial scale batches of active substance from the proposed manufacturer stored in the intended commercial package for up to 36 months under long term conditions (25ºC / 60% RH) and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided. Photostability testing following the ICH guideline Q1B was also conducted. The following parameters were tested: appearance, identification by IR and PXRD, water content, chiral purity by HPLC, related substances and assay. The absence of stability testing for fumaric acid was duly justified. All tested parameters remained unchanged during the testing period under both long-term and accelerated conditions and no significant trends were observed. Furthermore, the active substance was shown to be photostable.

A forced degradation study was performed under stressed conditions, demonstrating that the analytical procedures for impurities and assay are stability indicating.

The stability results indicate that the active substance manufactured by the proposed supplier is sufficiently stable. The stability results justify the proposed retest period without specific storage conditions in the proposed container.

<div style=\"page-break-after: always\"></div>

## 2.1.5. Finished medicinal product

## 2.1.5.1. Description of the product and pharmaceutical development

The finished product is presented as immediate release, film-coated tablets containing emtricitabine (200 mg), rilpivirine (25 mg) and tenofovir alafenamide (25 mg) as active substances. The tablets are white to off white, capsule-shaped, biconvex, bevel-edged, debossed with T7 on one side, with dimensions: 15.30 mm ± 0.3 mm x 7.15 mm ± 0.3 mm.

The finished product has been developed to be an essentially similar generic equivalent to the reference medicinal product, Odefsey. The applicant presented the quality target product profile (QTPP)Emtricitabine is a BCS class I compound, rilpivirine hydrochloride is a BCS class II compound and tenofovir alafenamide monofumarate is a BCS class III compound. All 3 active substances exhibit poor flow properties, and tenofovir alafenamide can hydrolyse in the presence of water. Therefore, a granulation approach was proposed for the production of emtricitabine/tenofovir alafenamide granules. Rilpivirine granules are produced by wet granulation. The granules are then mixed and compressed into tablets.

The choice and function of excipients was described. Compatibility of the chosen excipients with both active substances was confirmed by testing mixtures of active substances and proposed excipients. All excipients are well known pharmaceutical ingredients, and their quality is compliant with Ph. Eur. standards. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC. The formulation development has been adequately presented and is considered acceptable.

Dissolution methods are used considering the solubility profiles of the active substances for tenofovir alafenamide, emtricitabine and rilpivirine. The selected QC dissolution conditions are suitably justified.

A major objection was raised relating to both dissolution methods requesting justification of the amount of surfactant for the rilpivirine method and tightening of the specification limit for the emtricitabine/tenofovir method. In response to major objection, the applicant demonstrated that lower levels of surfactant lead to incomplete dissolution of rilpivirine and tightened the specification limit for the emtricitabine/tenofovir alafenamide method in line with EU guidance. This was considered acceptable, and the major objection was resolved.

Discriminatory power of the dissolution methods was investigated on batches manufactured with minor changes in formulation and process variables. No difference was observed for emtricitabine or tenofovir alafenamide release reflecting their solubility in aqueous media. However, the release rate or rilpivirine was significantly retarded in the over-compressed batches and those with excess binder. The dissolution methods are considered to be sufficiently discriminatory.

The applicant presented an adequate overview of manufacturing process development, including optimisation of the various unit operations.

The primary packaging is either OPA/aluminium/PE+desiccant+HDPE Coating - aluminium/PE blister packs or HDPE bottles with white opaque PP child-resistant closures with aluminium induction sealing liner wads along with desiccant. The materials comply with Ph. Eur. and EC requirements. The choice of the container closure systems has been validated by stability data and is adequate for the intended use of the product.

## 2.1.5.2. Manufacture of the product and process controls

The finished product is manufactured by one manufacturer. Satisfactory GMP documentation of the site

<div style=\"page-break-after: always\"></div>

has been provided.

The manufacturing process consists of six main steps: manufacture of emtricitabine/tenofovir alafenamide granules, manufacture of rilpivirine granules, blending of emtricitabine/tenofovir alafenamide and rilpivirine granules, compression, film-coating and packaging. The process is considered to be a standard manufacturing process.

The manufacturing process has been validated on the three production scale batches. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The applicant has also committed to perform validation of the proposed larger scale batch size prior to commercialisation, as documented in the validation protocol.

In-process controls and the associated analytical procedures have been clearly described and are considered adequate for this type of manufacturing process.

The packaging type and storage conditions for the bulk tablets were indicated and are acceptable.

## 2.1.5.3. Product specification

The finished product release specifications include appropriate tests for this kind of dosage form including description (visual), dimensions (in house), identification (HPLC, UV), dissolution (HPLC), uniformity of dosage units (Ph. Eur.), assay (HPLC), water content (KF), microbial quality (Ph. Eur.), and related substances (HPLC).

The shelf-life specifications are appropriately justified.

In the initial submission, the discussion of potentially mutagenic impurities was omitted, resulting in a major objection. In response, the applicant submitted a risk assessment for mutagenic impurities, showing that there is not risk of such impurities at significant levels in the finished product. The response was considered acceptable.

The potential presence of elemental impurities in the finished product was assessed following a riskbased approach in line with the ICH Q3D Guideline for Elemental Impurities. Batch analysis data on three finished product batches was provided, demonstrating that each relevant elemental impurity was not detected above 30% of the respective PDE. Based on the risk assessment, it can be concluded that it is not necessary to include any elemental impurity controls. The information on the control of elemental impurities is satisfactory.

A risk evaluation concerning the presence of nitrosamine impurities in the finished product was performed considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the 'European Medicines Regulatory Network approach for the implementation of the CHMP Opinion pursuant to Article 5(3) of Regulation (EC) Nº 726/2004 for nitrosamine impurities in human medicines (EMA/425645/2020). The only possible nitrosamine impurity is N -nitroso rilpivirine. Confirmatory testing was performed using a suitably sensitive validated analytical procedure and no nitrosamine impurity was detected. Therefore, it has been concluded that there is no risk of nitrosamines in the finished product and no specific control measures are deemed necessary.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

<div style=\"page-break-after: always\"></div>

Batch analysis data from three production scale batches was presented. All results were within the proposed specification limits. These batch analysis data confirm the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

The finished product is released on the market based on the above release specifications, through traditional final product release testing.

## 2.1.5.4. Stability of the product

Stability data from three production scale batches of finished product stored for up to 12 months under long term (25ºC / 60% RH) and intermediate (30ºC / 75% RH) conditions, and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided. The batches of finished product are identical to those proposed for marketing and were packed in both the primary packaging formats proposed for marketing. Samples were according to the shelf-life specifications. The analytical procedures used are stability indicating.

However, in the initial submission, only 6 months' long term and intermediate data was available, and the applicant had claimed a 24-month shelf-life, not stored above 30°C. Under accelerated conditions, out of specification (OOS) results were found for tenofovir alafenamide assay in both packaging formats resulting in a major objection. In response, the applicant submitted further data up to 12 months under long term and accelerated conditions and tightened the shelf-life specifications for water and several impurities. Considering the OOS results under accelerated conditions, no extrapolation of shelf-life is possible, and a maximum shelf-life of 12 months is possible, stored under long term conditions. With this response, the major objection was considered resolved.

In-use stability studies were carried out on the tablets stored in the HDPE bottles. The available data justifies an in-use shelf-life of 60 days (30 count bottles) and 90 days (90 count bottles).

A photostability study was carried out according to ICH Q1B it has been concluded that tablets are not photosensitive.

Based on available stability data, the proposed shelf-life of 12 months not stored above 25 ºC as stated in the SmPC (sections 6.3 and 6.4) is acceptable.

## 2.1.5.5. Adventitious agents

It is confirmed that the lactose is produced from milk from healthy animals in the same condition as those used to collect milk for human consumption and that the lactose has been prepared without the use of ruminant material other than calf rennet according to the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents Via Human and veterinary medicinal products.

No other excipients derived from animal or human origin have been used.

## 2.1.6. Discussion on chemical, and pharmaceutical aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner.

Five major objections were raised during the procedure, one relating to the proposed starting materials in the rilpivirine ASMF restricted part, one relating to the mutagenic risk assessment for tenofovir alafenamide ASMF, and three on the finished product related to the mutagenic risk assessment for the finished product, the dissolution methods (development of the rilpivirine method and specification

<div style=\"page-break-after: always\"></div>

limits for the emtricitabine/tenofovir alafenamide method), and the stability data considered inadequate to justify the initially proposed shelf-life. The applicant provided updated risk assessments for mutagenic impurities, indicating no risk for the finished product. Further justification was provided for the dissolution methods, including the use of a surfactant, and the release specification was tightened. Additional stability data was provided, the storage conditions were restricted and the shelflife reduced in line with the available real time data. All major objections were thus considered resolved.

The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.1.7. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

## 2.1.8. Recommendations for future quality development

Not applicable.

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

A non-clinical overview on the pharmacology, pharmacokinetics and toxicology based on up-to-date and adequate scientific literature was provided. The overview justified why there is no need to generate additional non-clinical pharmacology, pharmacokinetics and toxicology data. The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. The impurity profile has been discussed and was considered acceptable.

Pharmacodynamic, pharmacokinetic and toxicological properties of emtricitabine, rilpivirine and tenofovir alafenamide are well known. As they are a widely used, well-known active substances, the applicant has not provided additional studies and further studies are not required. The overview based on literature review is thus considered appropriate.

## 2.2.2. Ecotoxicity/environmental risk assessment

The applicant submitted an Environmental Risk Assessment in which it was demonstrated that the overall consumption of the active ingredients was stable or declining in all member states where the originator product was marketed and declining in the European Union as a whole year-on-year from 2020 to 2023.

<div style=\"page-break-after: always\"></div>

Table 1. Emtricitabine annual consumption data from 2020 to 2023 in Europe

<!-- image -->

|                |    2020 |    2021 |    2022 |    2023 |
|----------------|---------|---------|---------|---------|
| Austria        |   46    |   42.2  |   40.3  |   31.3  |
| Belgium        |  131.5  |  123.5  |  115.2  |  109.5  |
| Croatia        |    3.07 |    2.76 |    2.42 |    2.38 |
| Czech Republic |   37    |   38.7  |   37.9  |   34.1  |
| Denmark        |   11.3  |   12    |   10.2  |   10.1  |
| Finland        |   10.1  |    7.7  |    6.2  |    5.4  |
| France         | 1138.8  | 1111.4  | 1049.6  |  968    |
| Germany        |  376.3  |  386.7  |  359    |  343.9  |
| Ireland        |   51.3  |   48    |   49.3  |   51.5  |
| Italy          | 1161.9  | 1041.3  |  930.9  |  781.8  |
| Luxembourg     |    1.27 |    1.21 |    1.44 |    1.61 |
| Netherlands    |   64.6  |   58.6  |   61.4  |   58.6  |
| Norway         |   21.4  |   16.5  |   14.8  |   14.3  |
| Poland         |    0.09 |    0.07 |    0.09 |    0.04 |
| Portugal       |  271.9  |  265.8  |  263.7  |  251.1  |
| Slovakia       |    0.11 |    0.37 |    0.17 |    0.09 |
| Slovenia       |    7.61 |    6.77 |    6.39 |    5.67 |
| Spain          |  642.6  |  597.7  |  535.5  |  468.9  |
| Sweden         |   34    |   32.5  |   31.7  |   29.6  |
|                | 4010.9  | 3793.9  | 3516.1  | 3167.9  |

Furthermore, due to emergent HIV strains with (transmissible) drug resistance to individual active ingredients it can be assumed that the decrease in prescriptions will not be reversed in the future.

Thus, the ERA is expected to be similar and not increased.

## 2.2.3. Discussion on non-clinical aspects

No additional non-clinical studies are required.

Based on the data provided by the applicant it can be agreed that an approval and market introduction of Emtricitabine, Rilpivirine, Tenofovir Alafenamide Viatris film-coated tablets 200/25/25 mg should not be expected to result in an increased environmental exposure to the active ingredients.

## 2.2.4. Conclusion on the non-clinical aspects

The application for Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, film-coated tablets 200 mg/25 mg/25 mg can be approved from a non-clinical point of view.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Exemption

## Comparative Dissolution Studies

Comparative dissolution profiles of the test product Emtricitabine, Rilpivirine and Tenofovir Alafenamide 200 mg/25 mg/25 mg film-coated tablets and EU reference product Odefsey 200 mg/25 mg/25 mg filmcoated tablets (MAH: Gilead Sciences Ireland UC) were generated in different dissolution media.

Based on the dissolution study data available, the test product was found to be bioequivalent to the reference product.

During the procedure, the applicant provided additional dissolution profile data for the test product and EU reference product Odefsey 200 mg/25 mg/25 mg film-coated tablets (MAH: Gilead Sciences Ireland UC) in different dissolution media.

Based  on  additional  dissolution  data  the  current  description  of  choice  of  QC  dissolution  method  is considered sufficient.

## Tabular overview of clinical studies

To support the application, the applicant has submitted one bioequivalence study EMRTA-TFZ-1003.

| Iype of Study   | Study Identifier            | Location of Study Report                                                                        | Objective(s) of the Study                                                                                                                                                                                                                                                                                                                                                                                  | Study Design and Type of Control                                                                                                           | Test Product(s); Dosage Regimen; Route of Administration                                                                                                                                                                                                                           | Number of Subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Healthy Subjects or Diagnosis ofPatients   | Duration of Treatment   | Study Status; Type of Report   |
|-----------------|-----------------------------|-------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-------------------------|--------------------------------|
| BE              | Protocol EMRTA- D: TFZ-1003 | Clinical Study Report, PK Report, Event Listing. Adverse CRFs and Individual Subjects (5.3.1.2) | The objective of this study is to investigate thebioequivalenceof Mylan's test product (Emtricitabine, Rilpivirine, Tenofovir Alafenamide 200/25/25 mg film-coated tablets) with the Gilead reference SciencesIreland UC's product Odefsey 200 mg/25 mg/25 mg (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) film-coated tablets under fed conditions and also to evaluate the safety of the subjects | An open labelled, single-dose, randomized, two treatment, four period, replicate two-sequence, crossover, fully oral bioequivalence study. | Test Drug (T): Emtricitabine, Rilpivirine and Tenofovir Alafenamide Tablets 200 mg/25 mg/ 25 mg. 1 x 200 mg/25 mg/ 25 mg, Oral. Reference Drug (R): Odefsey 200 mg/25 mg/25 mg film coated tablets Emtricitabine/Rilp ivirine/Tenofovir alafenamide, 1 x 200 mg/25 mg 25 mg, Oral. | A total of fifty-four (54）subjects were enrolled in the study. Fifty-three (53) subjects completed period one, fifty-four (54）subjects completedperiod two,fifty (50) subjects completed period three and four. Therefore,fifty (50)subjects completed at least two periods(at least one test and one reference or tworeference)of the clinical portion of the study.Subjects who completed at least two periods (two reference)outof four periodsare considered for Swr calculationsof Tenofovir Alafenamide. i.e., 51 subjects. Subjects who completed at least twoperiods(at least one test and onereference or tworeference)out of four periods are considered for pharmacokinetic and statistical analysis of Tenofovir Alafenamide.i.e.,54 subjects. Subjects who completed first two periods of the study are considered for pharmacokinetic and  statistical analysis of Emtricitabine, Rilpivirine and Tenofovir.i.e., 53 subjects. | Healthy human adult subjects.              | Single dose             | Complet Abbrevia e; ted        |

<div style=\"page-break-after: always\"></div>

## 2.3.2. Clinical pharmacology

## 2.3.2.1. Pharmacokinetics

## Study EMRTA-TFZ-1003

Study Title: Single-dose, fed, bioequivalence study of Emtricitabine, Rilpivirine, Tenofovir Alafenamide 200/25/25 mg film coated tablets (test) and Odefsey 200 mg/25 mg/25 mg (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) film-coated tablets (Reference) manufactured by Gilead Sciences Ireland UC, in healthy adult human subjects.

## Methods

## · Study design

This was an open labelled, single-dose, randomised, two-treatment, four-period, two-sequence, fully replicate crossover study.

The objective of the Study was to investigate the bioequivalence of  test product (Emtricitabine, Rilpivirine, Tenofovir Alafenamide 200/25/25 mg film-coated tablets) with the Gilead Sciences Ireland UC's reference product Odefsey 200 mg/25 mg/25 mg (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) film-coated tablets under fed conditions and also to evaluate the safety of the subjects.

54 subjects were enrolled per protocol in the study and 50 subjects completed at least two periods (at least one test and one reference or two reference) of the clinical portion of the study. In order to minimise the possibility of a carry-over effect, a washout period of at least 28 days between dosing of period I to dosing of period II and a washout period of at least 10 days between dosing of period II to dosing of period III and dosing of period III to dosing of period IV was selected for the study.

Subjects were housed from the evening, maintaining at least 10 hours fasting prior to the start of consumption of high fat, high calorie breakfast on Day 1 until at least 72.00 hours post dose for period I, II and up to 24.00 hours post dose for period III, IV. Subjects received dinner the evening prior to dosing. Following a supervised overnight fast of at least 10 hours and 30 minutes after serving a highfat, high calorie breakfast, each subject received a single, oral dose 200 mg/25 mg/ 25 mg (1 x 200 mg/25 mg/ 25 mg) of either  Emtricitabine, Rilpivirine and Tenofovir Alafenamide Tablets 200 mg/25 mg/ 25 mg (Batch No. 2026813) or Gilead Sciences Ireland's Odefsey 200 mg/25 mg/25 mg film coated tablets Emtricitabine/Rilpivirine/Tenofovir alafenamide (Lot No.: CKSMKD1) with 240 mL of water. On the day of dosing, subjects received a standard low-fat meal at least 4 h, 8 h and 12 hours post-dose. The standard high-fat high-calorie breakfast consisted of chicken 80 gm with butter, 2 bread toast 40 gm with butter, hash brown potato 110 gm with butter, egg 60 gm fried in butter and 250 ml of whole milk with sugar and was consumed over a period of 30 minutes. The applicant was invited to provide details regarding calories and relative caloric content (%) of the meal.

Subjects consumed 240 mL of ambient temperature water at approximately 1.25 hours before dosing and 1 hour after dosing. Water was not permitted for 1 hour before and until 1 hour after dosing but was allowed at all other times. During period I and II, blood samples (1 × 5 mL) were collected in K3EDTA tubes from each subject within 1 hour prior to dose administration (0 hour) and post-dose at: 0.167, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 8.00, 12.00, 24.00, 36.00, 48.00 and 72.00 hours. During period III and IV, blood samples (1 × 4 mL) were collected in K3EDTA tubes from each subject within 1 hour prior to dose administration (0

<div style=\"page-break-after: always\"></div>

hour) and post-dose at: 0.167, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 4.50, 5.00 and 6.00 hours. Plasma samples were frozen in an upright position in a freezer unit with a set point of -70º C or colder with an acceptable operating range within -55°C to -90°C until shipment for analysis.

## · Test and reference products

Table 2. Test and reference products

| Product Characteristics                                     | Test Product (T)                                                                 | Reference Product (R)                          |
|-------------------------------------------------------------|----------------------------------------------------------------------------------|------------------------------------------------|
| Name                                                        | Emtricitabine, Rilpivirine and Tenofovir Alafenamide Tablets 200 mg/25 mg/ 25 mg | Odefsey 200 mg/25 mg/25 mg film coated tablets |
| Strength                                                    | 200 mg/25 mg/ 25 mg                                                              | 200 mg/25 mg/ 25 mg                            |
| Dosage form                                                 | Tablet                                                                           | Tablet                                         |
| Location of Certificate of Analysis                         | SYNCD-046- 22\\eCTD\\5.3.1.2/16.2.5                                                | SYNCD-046-22\\eCTD\\5.3.1.2/16.2.5               |
| Member State where the reference product is purchased from: | Not Applicable                                                                   | Netherlands                                    |

## · Population(s) studied

Healthy, non-smoking, male volunteers 18 years of age and older, weighing at least 50 kg with a Body Mass Index (BMI) less than or equal to 30.00 kg/m2 but greater than or equal to 18.50 kg/m2, who were judged to be healthy based on a pre-study physical examination and clinical laboratory tests

## · Analytical methods

## Validation of analytical methods

Three validation methods were developed for detection of emtricitabine and rilpivirine (Validation of liquid chromatographic method using tandem mass spectrometry detection for the determination of emtricitabine and rilpivirine in human plasma. Report Number: VR-296), tenofovir (Validation of ultra/high performance liquid chromatographic method using tandem mass spectrometry detection for the determination of tenofovir in ascorbic acid fortified human plasma. Report number: VR-195), and tenofovir alafenamide (Validation of high performance liquid chromatographic method using tandem mass spectrometry detection for the determination of tenofovir alafenamide in human plasma. Report number: VR-194) in human plasma as a support of clinical bioequivalence and bioavailability study EMRTA-TFZ-1003. The methods have been found to be reliable for detection of all analytes in the range of 25.135 to 4021.541 ng/mL for emtricitabine, in the range of 2.005 and 350.822 ng/mL for rilpivirine, in the range 0.2 to 24.995 ng/mL for tenofovir, and in the range of 5.00 to 500.011 ng/mL for tenofovir alafenamide.

During validation process following parameters were addressed and met the acceptance criteria for emtricitabine, rilpivirine, tenofovir and tenofovir alafenamide: specificity, selectivity, limit of quantitation, intra batch/run/day accuracy and precision, inter batch/run/day accuracy and precision. The stability analyses were performed to approve the stability for analytes and standards in conditions of processing, extraction and storage.

<div style=\"page-break-after: always\"></div>

The impact of concomitant drugs administration - paracetamol, pantoprazole, ondansetron and cetirizine were assessed and was revealed to have no effect on all analytes concentration. Also the estimation of each analyte in the presence of the rest analytes was approved to be reliable.

All parameters recommended for analytical method validation using chromatographic tandem mass spectrometric method were addressed (EMA/CHMP/ICH/172948/2019) and met the acceptance criteria.

## Bioanalyses (Study EMRTA-TFZ-1003)

The analytical portion of the bioequivalence study EMRTA-TFZ-1003 was conducted at the Bioanalytical Laboratory.

Tenofovir Alafenamide analysis was performed according to Analytical Method Procedure No. 'AMP194' and Study Protocol No. SP-EMRTA-TFZ-1003(TAF) using LC-MS/MS system. The lower limit of quantitation (LLOQ) was 5.015 ng/mL and the upper limit of quantitation (ULOQ) was 802.439 ng/mL. The total number of the received samples - 4607, the total number of analysed samples - 3959 (145 samples were missing). Calibration curve standards (CC) and quality control samples (QC) met the acceptance criteria for all the runs used for the final data. No pre-dose concentrations in the second period were observed. In the case of TAF for 8 subjects, the LLOQ was higher than the guidelinerecommended 1/20 of Cmax. Long term stability for Tenofovir Alafenamide was determined for 91 days and covers the longest period of samples storage (84 days). Incurred sample reanalysis was performed for 410 samples. All samples met acceptance criteria (100%).

Emtricitabine and Rilpivirine analysis was performed according to Analytical Method Procedure No. 'AMP-296' and Study Protocol No. SP-EMRTA-TFZ-1003(EMT+RPN) using LC-MS/MS system. The lower limit of quantification was 25.274 ng/mL for Emtricitabine, and 1.994 ng/mL for Rilpivirine. The upper limit of quantification was 25.274 ng/mL for Emtricitabine, and 1.994 ng/mL for Rilpivirine. The total number of the received samples - 2695, the total number of analysed samples - 2695 (5 samples were missing). Calibration curve standards (CC) and quality control (QC) samples met the acceptance criteria for all the runs used for the final data. No pre-dose concentrations in the second period were observed. 100% chromatograms were provided. Long term stability for Emtricitabine &amp; Rilpivirine was found to be stable for 109 days and covers the longest period of samples storage (95 days). Incurred sample reanalysis was performed for 219 samples. 98.6% samples for emtricitabine and 99.08% samples for rilpivirine met acceptance criteria.

Tenofovir analysis was performed according to Analytical Method Procedure No. 'AMP-195' and Study Protocol No. SP-EMRTA-TFZ-1003(TNF). using LC-MS/MS system. The lower limit of quantification was 0.199 ng/mL for tenofovir. The upper limit of quantification was 24.840 ng/ml. The total number of the received samples - 2695, the total number of analysed samples - 2695 (5 samples were missing). Calibration curve standards (CC) and quality control samples (QC) met the acceptance criteria for all the runs used for the final data. No pre-dose concentrations in the second period were observed. Tenofovir was found to be stable for 110 days and covers the longest period of samples storage (104 days). In the case of TnF for 1 subject, the LLOQ was higher than the guideline-recommended 1/20 of Cmax.

Incurred sample reanalysis was performed for 216 samples. 96.76% samples for tenofovir met acceptance criteria.

The bioanalyses submitted by the applicant were conducted in accordance with validated methods and guidelines. In all the provided bioanalyses, the number of haemolysed or lipemic samples is not indicated. Since the validation of the method for determining the active substances did not show a

<div style=\"page-break-after: always\"></div>

significant effect of haemolysis or lipaemia on the results, the lack of indication of the number of such samples is acceptable. In the case of TAF for 8 subjects and TNF for 1 subject, the LLOQ was higher than the guideline-recommended 1/20 of Cmax. The applicant presented an explanation about the LLOQ being higher than 1/20th of Cmax for some subjects. The response justifies that no analytical bias was introduced, and that the elevated LLOQ in these subjects does not impact the final pharmacokinetic results and bioequivalence assessment.

## · Pharmacokinetic variables

For tenofovir alafenamide AUC0-t, Cmax were considered primary PK parameters.

Cmax, AUC0-t and AUC0∞ for Emtricitabine and Cmax and AUC0 -72 for Rilpivirine were considered primary PK parameters.

Moreover, Tmax (hr), Kel (1/hr), t1/2 (hr) and Residual Area (%) were evaluated for Tenofovir Alafenamide and Emtricitabine

For Rilpivirine only Cmax , AUC0-72 and Tmax (hr) were evaluated.

## · Statistical methods

Statistical analysis was performed on the pharmacokinetic parameters of Emtricitabine, Rilpivirine, Tenofovir and Tenofovir Alafenamide using the General Linear Models Procedure (PROC GLM) of SAS Software (SAS Institute, Cary, NC) with the main effects of formulation, Period, Sequence and Subjects nested within Sequence as fixed effects.

The natural log transformed parameters Cmax, AUC0-t and AUC0∞ for Emtricitabine were statistically analysed. The natural log transformed parameters Cmax and AUC0-t for Tenofovir Alafenamide were statistically analysed. The natural log transformed parameters Cmax and AUC0-72 for Rilpivirine and Tenofovir were statistically analysed. The tests were performed to analyse the pharmacokinetic parameters using Least Squares Means. Ninety (90%) percent confidence intervals with Scaled Acceptance Range by widening of limits of Tenofovir Alafenamide were constructed for Cmax and ninety (90%) percent confidence intervals of AUC0-t to assess average bioequivalence between the two products. Ninety (90%) percent confidence intervals of Emtricitabine were constructed for Cmax, AUC0-t and AUC0∞ to assess average bioequivalence between the two products. Ninety (90%) percent confidence intervals of Rilpivirine were constructed for Cmax and AUC0-72 to assess average bioequivalence between the two products.

Tenofovir Alafenamide analyte statistically analysed by considering all four periods' data or at least two periods' data with a cross over of One Test and One Reference.

Pharmacokinetic parameters data of the subjects who received only two reference formulations were utilised in with in reference variability calculations and not included in the bioequivalence evaluation.

An outlier test was performed for Tenofovir Alafenamide prior to Statistical analysis using Studentized residual test on the reference data of Ln transformed Cmax to verify that the calculated intra-subject CV was reliable estimate. If subject was found to be outlier, then it was excluded from the calculation of reference product intra subject variability only, but included in statistical analysis.

The log-transformed pharmacokinetic parameters [Cmax and AUC0-t] for Tenofovir Alafenamide of Reference formulation was analysed using analysis of variance (ANOVA). ANOVA was performed using PROC GLM of SAS with the main effects of Sequence, Period and Subjects nested within Sequence as fixed effects.

<div style=\"page-break-after: always\"></div>

If within Reference Variability is &gt;30% then 90% CI for Cmax can be widened up to 69.84 % to 143.19% for TAF as mentioned below. The extent of the widening is defined based upon the within subject variability seen in the bioequivalence study using scaled-average-bioequivalence according to [U, L] = exp [±k·SWR], where U is the upper limit of the acceptance range, L is the lower limit of the acceptance range, k is the regulatory constant set to 0.760 and SWR is the within-subject standard deviation of the log-transformed values of Cmax of the reference product.

The possibility to widen the acceptance criteria based on high intra-subject variability does not apply to AUC0-t where the acceptance range should remain at 80.00 - 125.00% regardless of variability.

## Determination of Sample Size

Assuming the maximum intrasubject variability observed among primary pharmacokinetic parameters of ~40%, the following estimates are considered for the computation of sample size:

```
T/R ratio = 115 % Maximum Intra-Subject C.V (%) = ~40% Significance Level = 5% Power = 80%
```

Bioequivalence Limits = 80 - 125%

Based on the above estimate, a sample size of 48 subjects were sufficient to establish bioequivalence between formulations. However, taking into account the withdrawal &amp; drop-out subjects, a sample size of 54 subjects were considered for the study.

## · Results

## Disposition of Subjects

A total of 54 subjects were enrolled in the study.

53 subjects completed period one, 54 subjects completed period two, 50 subjects completed period three* and four. Therefore, fifty subjects completed at least two periods (at least one test and one reference or two reference) of the clinical portion of the study.

54 subjects were included for pharmacokinetic and statistical analysis of Emtricitabine, Rilpivirine, Tenofovir Alafenamide and Tenofovir.

<div style=\"page-break-after: always\"></div>

Table 3. Summary of subject disposition

|                                           | Sequence   | Sequence   |       |
|-------------------------------------------|------------|------------|-------|
|                                           | TRTR       | RTRT       | Total |
| Subjects Randomized                       | 27         | 27         | 54    |
| SubjectsSuccessfullyCompleted             | 24         | 26         | 50    |
| Subjectwhowithdrewconsent                 | 1          | 0          | 1     |
| Subjects Discontinued by the Investigator | 2          | 1          | 3     |

Treatment T = Emtricitabine, Rilpivirine, Tenofovir Alafenamide 200/25/25 mg film coated tablets (BATCH NO.:2026813)

Treatment R= Odefsy? 200 mg/25 mg/25 mg (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) film-coated tablets(LOT NO.:CKSMKD1)

Table 4. List of discontinued/withdrawn subjects

|   Period | Reasons for Discontinuation                                                                                                                                                                       |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       04 | Subject withdrawn from the study due to adverse event. Date:28/DEC/2023 Time:10:15 Last Treatment Received:T                                                                                      |
|       04 | Subject did not visit the facility for period four. Date:27/DEC/2023 Time:21:36 Last Treatment Received:R                                                                                         |
|       04 | Subject did not complete high fat high calorie breakfast due to AE (Vomiting). Hence not dosed in period four and withdrawn from the study. Date:28/DEC/2023 Time:08:58 Last Treatment Received:T |
|       04 | Subject withdrawn from the study due to adverse event before period four check-in. Date:27/DEC/2023 Time:20:28 Last Treatment Received:T                                                          |

## Protocol Deviations

A summary of protocol deviations was presented, including meals deviations, sample time collection deviations, sample buffering deviations, sample centrifugation deviations, sample shortage deviations, sample storage deviations, and vitals deviation.

<div style=\"page-break-after: always\"></div>

## PHARMACOKINETIC EVALUATIONS

Table 5. Pharmacokinetic results for Emtricitabine

|                     | Mean ± SD             | Mean ± SD             |
|---------------------|-----------------------|-----------------------|
| Parameters (Units)  | Test (T)              | Reference (R)         |
| Cmax (ng/mL)        | 1633.731 ± 352.7678   | 1624.442±412.7886     |
| AUC0-t (ng.hr/mL)   | 9696.920 ± 1471.7857  | 9435.139 ± 1424.4372  |
| AUC0-inf (ng.hr/mL) | 9990.157± 1472.7146   | 9745.853 ± 1446.2777  |
| *Tmax (hr)          | 2.330 (1.000 , 4.500) | 2.000 (1.000 , 4.500) |
| Kel (1/hr)          | 0.140 ± 0.0298        | 0.142 ± 0.0322        |
| t1/2 (hr)           | 5.254± 1.5064         | 5.290 ± 1.9606        |
| Residual Area (%)   | 3.28 ± 0.844          | 3.22±0.752            |

Figure 4. Mean linear plot for Emtricitabine

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 6. BE summary tables for Emtricitabine

| Pharmacokinetic parameter   |   Geometric Least Squares Means (Test,T) |   Geometric Least Squares Means (Reference,R) |   Ratio (T/R) (%) | 90% Confidence Limits (T vs. R)   |   Intra Subject CV % |   Power (%) |
|-----------------------------|------------------------------------------|-----------------------------------------------|-------------------|-----------------------------------|----------------------|-------------|
| Ln(Cmax)(ng/mL)             |                                  1595.83 |                                       1580.33 |            100.98 | (95.85, 106.39)                   |                16.12 |         100 |
| Ln(AUCo- t)(ng.hr/mL)       |                                  9587.76 |                                       9329.99 |            102.76 | (100.67, 104.90)                  |                 6.34 |         100 |
| Ln(AUCo-inf) (ng.hr/mL)     |                                  9883.61 |                                       9622.8  |            102.71 | (100.69, 104.77)                  |                 6.05 |         100 |

Table 7. Pharmacokinetic results for Rilpivirine

Figure 5. Mean linear plot for Rilpivirine

|                    | Mean±SD               | Mean±SD               |
|--------------------|-----------------------|-----------------------|
| Parameters (Units) | Test (T)              | Reference (R)         |
| Cmax ( (ng/mL)     | 210.840± 56.9183      | 191.059± 51.6425      |
| AUC0-72 (ng.hr/mL) | 4321.016±1229.7751    | 3904.038±1055.3741    |
| *Tmax (hr)         | 4.500 (2.000 , 6.000) | 4.500 (2.670 , 6.000) |

MylanStudy Code:EMRTA-TFZ-1003

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 8. BE summary tables for Rilpivirine

| Pharmacokinetic parameter   |   Geometric Least Squares Means (Test,T) |   Geometric Least Squares Means (Reference,R) |   Ratio (T/R) (%) | 90% Confidence Limits (T vs. R)   |   Intra Subject CV % |   Power (%) |
|-----------------------------|------------------------------------------|-----------------------------------------------|-------------------|-----------------------------------|----------------------|-------------|
| Ln(Cmax)(ng/mL)             |                                  202.092 |                                       183.163 |            110.33 | (103.76, 117.33)                  |                19.05 |         100 |
| Ln(AUC0-72) (ng.hr/mL)      |                                 4148.88  |                                      3755.68  |            110.47 | (105.08, 116.13)                  |                15.44 |         100 |

Table 9. Pharmacokinetic results for Tenofovir (supportive)

Figure 6. Mean linear plot for Tenofovir (supportive)

|                      | Mean±SD               | Mean±SD               |
|----------------------|-----------------------|-----------------------|
| Parameter's  (Units) | Test (T)              | Reference (R)         |
| Cmax (ng/mL)         | 7.762±2.0734          | 7.428±1.4725          |
| AUC0-72 (ng.hr/mL)   | 213.049± 43.1568      | 207.534±32.7932       |
| *Tmax (hr)           | 3.000 (1.250 , 4.500) | 3.000 (1.500 , 5.000) |

Mylan Study Code:EMRTA-TFZ-1003

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 10. Pharmacokinetic results for Tenofovir Alafenamide

Figure 7. Mean linear plot for Tenofovir Alafenamide

|                     | Mean ± SD             | Mean ± SD            |
|---------------------|-----------------------|----------------------|
| Parameter's (Units) | Test (T)              | Reference (R)        |
| Cmax (ng/mL)        | 237.732±123.5578      | 255.409±120.9911     |
| AUC0-t (ng.hr/mL)   | 300.178±88.3080       | 310.352±81.5924      |
| AUC0-inf (ng.hr/mL) | 309.096 ± 89.3418     | 316.399 ±82.4431     |
| *Tmax (hr)          | 1.510 (0.670 , 4.500) | 1.500 (0.330, 4.500) |
| Kel (1/hr)          | 1.676± 0.4851         | 1.616± 0.4169        |
| t1/2 (hr)           | 0.454± 0.1517         | 0.465 ± 0.1538       |
| Residual Area (%)   | 2.18 ± 1.606          | 2.07± 1.327          |

MylanStudy code:EMTRA-TFZ-1003

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 11. BE summary tables for Tenofovir Alafenamide

| Pharmacokineti parameter C   |   Geometri cLeast Squares Means (Test,T) |   Geometric Least Squares Means (Reference,R ） |   Rati 0 (T/R ） (%) | 90% Confidenc e Limits (T vs. R)   |   Within subject standard deviatio n (SWR) |   Intra- Subject %CV of Referenc e | Scaled Acceptanc e Range (%)   |   Intra Subjec t CV % | Power (%)   |
|------------------------------|------------------------------------------|------------------------------------------------|---------------------|------------------------------------|--------------------------------------------|------------------------------------|--------------------------------|-----------------------|-------------|
| Ln(Cmax)(ng/mL)              |                                  209.988 |                                        228.329 |               91.97 | (85.05, 99.44)                     |                                   0.366272 |                              37.89 | (75.70, 132.10)                |                 34.58 | 95.63       |
| Ln(AUCO- t)(ng.hr/mL)        |                                  287.469 |                                        298.841 |               96.19 | (92.39, 100.15)                    |                                   0.176828 |                              17.82 | (80.00, 125.00)                |                 17.48 | 100.0 0     |

Statistical analyses of the pharmacokinetic data reveals that the 90% confidence intervals are within the acceptable bioequivalent range of 80.00% and 125.00% for Cmax and AUC0-inf of Emtricitabine. Statistical analyses of the pharmacokinetic data reveals that the 90% confidence intervals are within the acceptable bioequivalent range of 80.00% and 125.00% for AUC0-t of Emtricitabine and Tenofovir Alafenamide. Statistical analyses of the pharmacokinetic data reveals that the 90% confidence intervals are within the acceptable bioequivalent range of 80.00% and 125.00% for Cmax and AUC072 of Rilpivirine.

The intrasubject variability of reference (%ISCV) for Tenofovir Alafenamide was 37.89% for Cmax which was more than 30%. Therefore, bioequivalence was assessed using the scaled average bioequivalence approach. The calculated 90% confidence intervals (85.05% and 99.44%) of Tenofovir Alafenamide were within the acceptance limits of 75.70% to 132.10%. However, since 90% CI for Cmax were within conventional criteria, widening of acceptance criteria for Cmax was not needed.

Table 12. Plasma Emtricitabine concentration (ng/mL) - primary analysis

| Pharmacokinetic parameter   |   Sequence |   Formulation |   Period |
|-----------------------------|------------|---------------|----------|
| Ln(C max )(ng/mL)           |     0.126  |        0.755  |   0.7555 |
| Ln(AUC 0-t )(ng.hr/mL)      |     0.9591 |        0.0312 |   0.872  |
| Ln(AUC 0-inf )(ng.hr/mL)    |     0.9769 |        0.0287 |   0.8867 |

Cmax: Sequence,  formulation  and  period  effects  were  found  to  be  statistically  insignificant  on  lntransformed scale.

AUC0-t: Sequence and period effects were found to be statistically insignificant on ln-transformed scale. Formulation effects were found to be statistically significant on ln-transformed scale.

AUC0-inf: Sequence and period effects were found to be statistically insignificant on ln-transformed scale. Formulation effects were found to be statistically significant on ln-transformed scale.

## Justification for Significant Formulation Effect:

When the intra-subject variability is low, and/or sample size is large (the statistical power is high), very small difference between the formulations can be detected, consequently, a statistically significant treatment effect would be shown. However, this small difference will not be clinically relevant as long

<div style=\"page-break-after: always\"></div>

as the entire 90% confidence interval of the geometric mean ratio is contained within the bioequivalence criteria range (80.00-125.00%). In other words, the treatment effect for AUC0-t and AUC0-inf is statistically significant, but not clinically significant.

Table 13. Plasma Rilpivirine concentration (ng/mL) - primary analysis

| Pharmacokinetic parameter   |   Sequence |   Formulation |   Period |
|-----------------------------|------------|---------------|----------|
| Ln(C max )(ng/mL)           |     0.6822 |        0.0099 |   0.0666 |
| Ln(AUC 0-72 )(ng.hr/mL)     |     0.4572 |        0.0016 |   0.0027 |

## Cmax:

Sequence and period effects were found to be statistically insignificant on ln-transformed scale. Formulation effect was found to be statistically significant on ln-transformed scale.

## AUC0-72:

Sequence effect  was  found  to  be  statistically  insignificant  on  ln-transformed  scale.  Formulation  and period effects were found to be statistically significant on ln-transformed scale.

## Justification for Significant Formulation Effect:

When the intra-subject variability is low, and/or sample size is large (the statistical power is high), very small difference between the formulations can be detected, consequently, a statistically significant treatment effect would be shown. However, this small difference will not be clinically relevant as long as the entire 90% confidence interval of the geometric mean ratio is contained within the bioequivalence criteria range (80.00-125.00%). In other words, the treatment effect for Cmax and AUC0-72 is statistically significant, but not clinically significant.

## Justification for significant Period effect:

In principle, significant period effect might be obtained due to an equal carry-over effect, or a true period effect.

An equal carry-over effect might be obtained if the washout period is too short to allow the complete elimination of the drug administered in previous period. However, this can be checked by the pre-dose concentration at the later periods if this is true. In current study, the washout out period is sufficiently long so there is no pre-dose concentration in the second period. Therefore, equal carry-over effect is very unlikely. Even if it exists, since both test and reference would be affected the same way, the comparison of test and reference would not be affected.

A true period effect would mean that physiological status of all (or most) subjects, and / or environmental conditions, changed between different periods that affect the bioavailability of the drug product.

True period effect is very unlikely because firstly, subjects in BE studies are normal human volunteers whose physical condition is unlikely to change radically from one period of a crossover trial to another, unlike patients whose disease state may progress during the course of even a short trial; secondly, it is a study of single doses of the drug formulations and is thus unlikely to result in a marked change in a subject's physical condition; thirdly, since this is a single centre study, even if there is a drastic

<div style=\"page-break-after: always\"></div>

environmental change, all subjects would be equally affected, therefore the comparison between Test and Reference would not be impacted.

In addition, even if there is a true period effect, bioequivalence assessment will not be influenced by it as both Test and Reference will be affected similarly in crossover study.

Table 14. Plasma Tenofovir concentration (ng/mL) - primary analysis

| Pharmacokinetic parameter   |   Sequence |   Formulation |   Period |
|-----------------------------|------------|---------------|----------|
| Ln(C max )(ng/mL)           |     0.2688 |         0.372 |   0.0178 |
| Ln(AUC 0-72 )(ng.hr/mL)     |     0.1892 |         0.33  |   0.0003 |

## Cmax:

Sequence and formulation effects were found to be statistically insignificant on ln-transformed scale. Period effect was found to be statistically significant on ln-transformed scale.

## AUC0-72:

Sequence and formulation effects were found to be statistically insignificant on ln-transformed scale. Period effect was found to be statistically significant on ln-transformed scale.

## Justification for significant Period effect:

In principle, significant period effect might be obtained due to an equal carry-over effect, or a true period effect.

An equal carry-over effect might be obtained if the washout period is too short to allow the complete elimination of the drug administered in previous period. However, this can be checked by the pre-dose concentration at the later periods if this is true. In current study, the washout out period is sufficiently long so there is no pre-dose concentration in the second period. Therefore, equal carry-over effect is very unlikely. Even if it exist, since both test and reference would be affected the same way, the comparison of test and reference would not be affected.

A true period effect would mean that physiological status of all (or most) subjects, and / or environmental conditions, changed between different periods that affect the bioavailability of the drug product.

True period effect is very unlikely because firstly, subjects in BE studies are normal human volunteers whose physical condition is unlikely to change radically from one period of a crossover trial to another, unlike patients whose disease state may progress during the course of even a short trial; secondly, it is a study of single doses of the drug formulations and is thus unlikely to result in a marked change in a subject's physical condition; thirdly, since this is a single centre study, even if there is a drastic environmental change, all subjects would be equally affected, therefore the comparison between Test and Reference would not be impacted.

In addition, even if there is a true period effect, bioequivalence assessment will not be influenced by it as both Test and Reference will be affected similarly in crossover study.

<div style=\"page-break-after: always\"></div>

Table 15. Plasma Tenofovir Alafenamide concentration (ng/mL) - primary analysis

| Pharmacokinetic parameter   |   Sequence |   Formulation | Period   |
|-----------------------------|------------|---------------|----------|
| Ln(C max )(ng/mL)           |     0.2077 |        0.0782 | 0.0008   |
| Ln(AUC 0-t )(ng.hr/mL)      |     0.4127 |        0.1136 | <.0001   |

## Cmax:

Sequence and formulation effects were found to be statistically insignificant on ln-transformed scale. Period effect was found to be statistically significant on ln-transformed scale.

## AUC0-t:

Sequence and formulation effects were found to be statistically insignificant on ln-transformed scale. Period effect was found to be statistically significant on ln-transformed scale.

## Justification for significant Period effect:

In principle, significant period effect might be obtained due to an equal carry-over effect, or a true period effect.

An equal carry-over effect might be obtained if the washout period is too short to allow the complete elimination of the drug administered in previous period. However, this can be checked by the pre-dose concentration at the later periods if this is true. In current study, the washout out period is sufficiently long so there is no pre-dose concentration in the second period. Therefore, equal carry-over effect is very  unlikely.  Even  if  it  exist,  since  both  test  and  reference  would  be  affected  the  same  way,  the comparison of test and reference would not be affected.

A true period effect would mean that physiological status of all (or most) subjects, and / or environmental conditions, changed between different periods that affect the bioavailability of the drug product.

True period effect is very unlikely because firstly, subjects in BE studies are normal human volunteers whose physical condition is unlikely to change radically from one period of a crossover trial to another, unlike patients whose disease state may progress during the course of even a short trial; secondly, it is a study of single doses of the drug formulations and is thus unlikely to result in a marked change in a subject's  physical  condition;  thirdly,  since  this  is  a  single  centre  study,  even  if  there  is  a  drastic environmental change, all subjects would be equally affected, therefore the comparison between Test and Reference would not be impacted.

In addition, even if there is a true period effect, bioequivalence assessment will not be influenced by it as both Test and Reference were affected similarly in crossover study.

Therefore, based on the results of the Study EMRTA-TFZ-1003 Mylan's Emtricitabine, Rilpivirine and Tenofovir Alafenamide Tablets 200 mg/25 mg/ 25 mg can be considered bioequivalent to Gilead Sciences Ireland's Odefsey 200 mg/25 mg/25 mg film coated tablets Emtricitabine/Rilpivirine/Tenofovir alafenamide following a single, oral 200 mg/25 mg/ 25 mg (1 x 200 mg/25 mg/ 25 mg) dose administered under fed conditions.

## · Safety data

Nine subjects experienced a total of twelve adverse events over the course of the study. The AEs were mild to moderate in severity. No Serious Adverse Events were reported

<div style=\"page-break-after: always\"></div>

The reported AE following administration of Treatment T was vomiting which was reported by 3/54 (5.55%) subjects, pruritus which was reported by 1/54 (1.85%) subject, hepatic enzymes increased which was reported by 1/54 (1.85%) subject, headache which was reported by 1/54 (1.85%) subject and hypertriglyceridaemia which was reported by 1/54 (1.85%) [two events in same subject] subject.

The reported AE following administration of Treatment R was vomiting which was reported by 2/54 (3.70%) subjects, headache which was reported by 1/54 (1.85%) subject and tinia cruris which was reported by 1/54 (1.85%) subject.

There were 7 AEs [vomiting (two events), pruritus, hepatic enzyme increased, headache and hypertriglyceridaemia (two events)] considered at least possibly related and one AE (vomiting) that was considered as unlikely related to the oral administration of Emtricitabine, Rilpivirine and Tenofovir Alafenamide Tablets 200 mg/25 mg/ 25 mg. There was one AE (headache) considered as possibly related and three (03) AEs [vomiting (two events) and tinea cruris] unlikely related to the oral administration of Gilead Sciences Ireland's Odefsey 200 mg/25 mg/25 mg film coated tablets Emtricitabine/Rilpivirine/Tenofovir alafenamide.

Table 16. Adverse events: number observed and rate

| TreatmentT:TreatmentEmergentAdverseEvents N=54a                                | TreatmentT:TreatmentEmergentAdverseEvents N=54a   | TreatmentT:TreatmentEmergentAdverseEvents N=54a                                     | TreatmentT:TreatmentEmergentAdverseEvents N=54a                                     | TreatmentT:TreatmentEmergentAdverseEvents N=54a                                     | TreatmentT:TreatmentEmergentAdverseEvents N=54a                                     | TreatmentT:TreatmentEmergentAdverseEvents N=54a                                     | TreatmentT:TreatmentEmergentAdverseEvents N=54a                                     | TreatmentT:TreatmentEmergentAdverseEvents N=54a   | TreatmentT:TreatmentEmergentAdverseEvents N=54a   | TreatmentT:TreatmentEmergentAdverseEvents N=54a   |
|--------------------------------------------------------------------------------|---------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                                                                |                                                   | Subjects Who Experienced Indicated AE at Least Once by Intensity and Relationship b | Subjects Who Experienced Indicated AE at Least Once by Intensity and Relationship b | Subjects Who Experienced Indicated AE at Least Once by Intensity and Relationship b | Subjects Who Experienced Indicated AE at Least Once by Intensity and Relationship b | Subjects Who Experienced Indicated AE at Least Once by Intensity and Relationship b | Subjects Who Experienced Indicated AE at Least Once by Intensity and Relationship b | Total No. of AEsc                                 | Total No. of AEsc                                 | Total No. of AEsc                                 |
|                                                                                |                                                   | Mild                                                                                | Mild                                                                                | Moderate                                                                            | Moderate                                                                            | Severe                                                                              | Severe                                                                              | Total                                             | Total                                             | Total                                             |
| System Organ Class                                                             | Preferred Term                                    | Related                                                                             | NR                                                                                  | Related                                                                             | NR                                                                                  | Related                                                                             | NR                                                                                  | Related                                           | NR                                                | Overall                                           |
| Gastrointestinaldisorders                                                      | Vomiting                                          | 2 (3.70%) [04,31]                                                                   | 1 (1.85%) [46]                                                                      | 0                                                                                   | 0                                                                                   | 0                                                                                   | 0                                                                                   | 2                                                 | 1                                                 | 3                                                 |
| Investigations                                                                 | Hepatic enzyme increased                          | 1 (1.85%) [42]                                                                      | 0                                                                                   | 0                                                                                   | 0                                                                                   | 0                                                                                   | 0                                                                                   | 1                                                 | 0                                                 |                                                   |
| Metabolism andnutritiondisorders                                               | Hypertriglyceridaemia                             | (1.85%) [54]                                                                        | 0                                                                                   | (1.85%) [54]                                                                        | 0                                                                                   | 0                                                                                   | 0                                                                                   | 2                                                 | 0                                                 | 2                                                 |
| Nervous system disorders                                                       | Headache                                          | (1.85%) [50]                                                                        | 0                                                                                   | 0                                                                                   | 0                                                                                   | 0                                                                                   | 0                                                                                   |                                                   | 0                                                 |                                                   |
| Skin and subcutaneous tissue disorders                                         | Pruritus                                          | 0                                                                                   | 0                                                                                   | 1 (1.85%) [37]                                                                      | 0                                                                                   | 0                                                                                   | 0                                                                                   | 1                                                 | 0                                                 |                                                   |
| Total Number of AEs Reported                                                   |                                                   |                                                                                     |                                                                                     |                                                                                     |                                                                                     |                                                                                     |                                                                                     |                                                   |                                                   | 8                                                 |
| Total Number of SubjectsReporting At Least One AE byIntensity and Relationship |                                                   | 5                                                                                   |                                                                                     | 2                                                                                   | 0                                                                                   | 0                                                                                   | 0                                                                                   |                                                   |                                                   |                                                   |

| TreatmentT:TreatmentEmergentAdverseEvents N =54a                                | TreatmentT:TreatmentEmergentAdverseEvents N =54a   | TreatmentT:TreatmentEmergentAdverseEvents N =54a        | TreatmentT:TreatmentEmergentAdverseEvents N =54a        | TreatmentT:TreatmentEmergentAdverseEvents N =54a   | TreatmentT:TreatmentEmergentAdverseEvents N =54a   | TreatmentT:TreatmentEmergentAdverseEvents N =54a   | TreatmentT:TreatmentEmergentAdverseEvents N =54a   | TreatmentT:TreatmentEmergentAdverseEvents N =54a   | TreatmentT:TreatmentEmergentAdverseEvents N =54a   | TreatmentT:TreatmentEmergentAdverseEvents N =54a   |
|---------------------------------------------------------------------------------|----------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
|                                                                                 |                                                    | SubjectsWhoExperiencedIndicatedAEatLeastOncebyIntensity | SubjectsWhoExperiencedIndicatedAEatLeastOncebyIntensity | Moderate                                           | Moderate                                           | Severe                                             | Severe                                             | Total No. of AEsc                                  | Total No. of AEsc                                  | Total No. of AEsc                                  |
|                                                                                 | Preferred Term                                     | Mild                                                    | Mild                                                    |                                                    |                                                    |                                                    |                                                    | Total                                              | Total                                              | Total                                              |
| System Organ Class                                                              |                                                    | Related                                                 | NR                                                      | Related                                            | NR                                                 | Related                                            | NR                                                 | Related                                            | NR                                                 | Overall                                            |
| Total Number of Subjects Reporting At Least One AE Over the Course of the Study |                                                    |                                                         |                                                         |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    | 7                                                  |

(%)percentageof subjectsreporting at least oneincidence of respective adverse event

Subject numbers of subjectsreporting at least one incidence ofrespective adverse event

NOTE: Superscript above the subject number indicates the number of multiple occurrences of the indicated AE experienced by that subject.

Note: AEs deemed as Unlikely, or Unrelated/Not Related are included in the NR column. AEs deemed Definitely, Probably, and Possibly related are included in the Related column.

c = Total number of reported adverse events

<div style=\"page-break-after: always\"></div>

| Treatinent R:Treatment Emergent Adverse Events N=54a                                                      | Treatinent R:Treatment Emergent Adverse Events N=54a   | Treatinent R:Treatment Emergent Adverse Events N=54a                               | Treatinent R:Treatment Emergent Adverse Events N=54a                               | Treatinent R:Treatment Emergent Adverse Events N=54a                               | Treatinent R:Treatment Emergent Adverse Events N=54a                               | Treatinent R:Treatment Emergent Adverse Events N=54a                               | Treatinent R:Treatment Emergent Adverse Events N=54a                               | Treatinent R:Treatment Emergent Adverse Events N=54a   | Treatinent R:Treatment Emergent Adverse Events N=54a   | Treatinent R:Treatment Emergent Adverse Events N=54a   |
|-----------------------------------------------------------------------------------------------------------|--------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                                                                           |                                                        | SubjectsWho Experienced Indicated AE at Least Once by Intensity and Relationship b | SubjectsWho Experienced Indicated AE at Least Once by Intensity and Relationship b | SubjectsWho Experienced Indicated AE at Least Once by Intensity and Relationship b | SubjectsWho Experienced Indicated AE at Least Once by Intensity and Relationship b | SubjectsWho Experienced Indicated AE at Least Once by Intensity and Relationship b | SubjectsWho Experienced Indicated AE at Least Once by Intensity and Relationship b | Total No. of AEsc                                      | Total No. of AEsc                                      | Total No. of AEsc                                      |
|                                                                                                           |                                                        | Mild                                                                               | Mild                                                                               | Moderate                                                                           | Moderate                                                                           | Severe                                                                             | Severe                                                                             | Total                                                  | Total                                                  | Total                                                  |
| System Organ Class                                                                                        | Preferred Term                                         | Related                                                                            | NR                                                                                 | Related                                                                            | NR                                                                                 | Related                                                                            | NR                                                                                 | Related                                                | NR                                                     | OVERA LL                                               |
| Gastrointestinaldisorders                                                                                 | Vomiting                                               | 0                                                                                  | 2 (3.70%) [10,49]                                                                  | 0                                                                                  | 0                                                                                  | 0                                                                                  | 0                                                                                  | 0                                                      | 2                                                      | 2                                                      |
| Infections and infestations                                                                               | Tinea cruris                                           | 0                                                                                  | 1 (1.85%) [37]                                                                     | 0                                                                                  | 0                                                                                  | 0                                                                                  | 0                                                                                  | 0                                                      | 1                                                      | 1                                                      |
| Nervous system disorders                                                                                  | Headache                                               | (1.85%) [10]                                                                       | 0                                                                                  | 0                                                                                  | 0                                                                                  | 0                                                                                  | 0                                                                                  | 1                                                      | 0                                                      |                                                        |
| Total NumberofAEsReported                                                                                 |                                                        |                                                                                    |                                                                                    |                                                                                    |                                                                                    |                                                                                    |                                                                                    |                                                        | 3                                                      | 4                                                      |
| Total Number of Subjects Reporting At Least OneAE byIntensity and Relationship                            |                                                        | 1                                                                                  | 3                                                                                  | 0                                                                                  | 0                                                                                  | 0                                                                                  | 0                                                                                  |                                                        |                                                        |                                                        |
| Total NumberofSubjectsReportingAt Least OneAE Over the Course of the Study AEcodingwithMedDRAversion 26.1 |                                                        |                                                                                    |                                                                                    |                                                                                    |                                                                                    |                                                                                    |                                                                                    |                                                        |                                                        |                                                        |

| StudyParticipation [ForAEsnot definitively attributable to an individual treatment,if applicable]:StudyEmergent AdverseEvents N =54a   | StudyParticipation [ForAEsnot definitively attributable to an individual treatment,if applicable]:StudyEmergent AdverseEvents N =54a   | StudyParticipation [ForAEsnot definitively attributable to an individual treatment,if applicable]:StudyEmergent AdverseEvents N =54a   | StudyParticipation [ForAEsnot definitively attributable to an individual treatment,if applicable]:StudyEmergent AdverseEvents N =54a   | StudyParticipation [ForAEsnot definitively attributable to an individual treatment,if applicable]:StudyEmergent AdverseEvents N =54a   | StudyParticipation [ForAEsnot definitively attributable to an individual treatment,if applicable]:StudyEmergent AdverseEvents N =54a   | StudyParticipation [ForAEsnot definitively attributable to an individual treatment,if applicable]:StudyEmergent AdverseEvents N =54a   | StudyParticipation [ForAEsnot definitively attributable to an individual treatment,if applicable]:StudyEmergent AdverseEvents N =54a   | StudyParticipation [ForAEsnot definitively attributable to an individual treatment,if applicable]:StudyEmergent AdverseEvents N =54a   | StudyParticipation [ForAEsnot definitively attributable to an individual treatment,if applicable]:StudyEmergent AdverseEvents N =54a   | StudyParticipation [ForAEsnot definitively attributable to an individual treatment,if applicable]:StudyEmergent AdverseEvents N =54a   |
|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                        |                                                                                                                                        | SubjectsWhoExperiencedIndicatedAEat LeastOncebyIntensity and Relationship b                                                            | SubjectsWhoExperiencedIndicatedAEat LeastOncebyIntensity and Relationship b                                                            | SubjectsWhoExperiencedIndicatedAEat LeastOncebyIntensity and Relationship b                                                            | SubjectsWhoExperiencedIndicatedAEat LeastOncebyIntensity and Relationship b                                                            | SubjectsWhoExperiencedIndicatedAEat LeastOncebyIntensity and Relationship b                                                            | SubjectsWhoExperiencedIndicatedAEat LeastOncebyIntensity and Relationship b                                                            | Total No. of AEsc                                                                                                                      | Total No. of AEsc                                                                                                                      | Total No. of AEsc                                                                                                                      |
|                                                                                                                                        |                                                                                                                                        | Mild                                                                                                                                   | Mild                                                                                                                                   | Moderate                                                                                                                               | Moderate                                                                                                                               | Severe                                                                                                                                 | Severe                                                                                                                                 | Total                                                                                                                                  | Total                                                                                                                                  | Total                                                                                                                                  |
| System Organ Class                                                                                                                     | Preferred Term                                                                                                                         | Related                                                                                                                                | NR                                                                                                                                     | Related                                                                                                                                | NR                                                                                                                                     | Related                                                                                                                                | NR                                                                                                                                     | Related                                                                                                                                | NR                                                                                                                                     | OVERALL                                                                                                                                |
| Total Number of AEs Reported                                                                                                           |                                                                                                                                        |                                                                                                                                        |                                                                                                                                        |                                                                                                                                        |                                                                                                                                        |                                                                                                                                        |                                                                                                                                        | 0                                                                                                                                      | 0                                                                                                                                      | 0                                                                                                                                      |
| Total Number of Subjects ReportingAt Least One AE by Intensity and Relationship                                                        |                                                                                                                                        | 0                                                                                                                                      | 0                                                                                                                                      | 0                                                                                                                                      | 0                                                                                                                                      | 0                                                                                                                                      | 0                                                                                                                                      |                                                                                                                                        |                                                                                                                                        |                                                                                                                                        |
| Total Number of Subjects Reporting At Least OneAE Over theCourseoftheStudy                                                             |                                                                                                                                        |                                                                                                                                        |                                                                                                                                        |                                                                                                                                        |                                                                                                                                        |                                                                                                                                        |                                                                                                                                        |                                                                                                                                        |                                                                                                                                        | 0                                                                                                                                      |

(%)percentage of subjectsreporting atleast oneincidenceofrespective adverse event

NOTE: Superscript above the subject number indicates the number of multiple occurrences of the indicated AE experienced by that subject.

Subject numbers of subjects reporting at least one incidence of respective adverse event

c=Total number of reported adverse events

Note:AEs deemed as Unlikely,or Unrelated/Not Related are included in theNR column.AEs deemedDefinitely,Probably,andPossibly related are includedin the Related column.

## Table 17. Listing of all adverse events by body system

| Body System a                          | Adverse Event (Preferred Term) a   | Serious   | Intensit y   | Relatio nship   |   Period | Treatment   |
|----------------------------------------|------------------------------------|-----------|--------------|-----------------|----------|-------------|
| Gastrointestinal disorders             | Vomiting                           | N         | Mild         | Possible        |       04 | T           |
| Nervous system disorders               | Headache                           | N         | Mild         | Possible        |       02 | R           |
| Gastrointestinal disorders             | Vomiting                           | N         | Mild         | Unlikel y       |       03 | R           |
| Gastrointestinal disorders             | Vomiting                           | N         | Mild         | Possible        |       01 | T           |
| Skin and subcutaneous tissue disorders | Pruritus                           | N         | Moderat e    | Possible        |       01 | T           |
| Infections and infestations            | Tinea cruris                       | N         | Mild         | Unlikel y       |       02 | R           |
| Investigations                         | Hepatic enzyme increased           | N         | Mild         | Possible        |       03 | T           |

<div style=\"page-break-after: always\"></div>

| Body System a                      | Adverse Event (Preferred Term) a   | Serious   | Intensit y   | Relatio nship   |   Period | Treatment   |
|------------------------------------|------------------------------------|-----------|--------------|-----------------|----------|-------------|
| Gastrointestinal disorders         | Vomiting                           | N         | Mild         | Unlikel y       |       04 | T           |
| Gastrointestinal disorders         | Vomiting                           | N         | Mild         | Unlikel y       |       03 | R           |
| Nervous system disorders           | Headache                           | N         | Mild         | Possible        |       02 | T           |
| Metabolism and nutrition disorders | Hypertriglycerida emia             | N         | Mild         | Possible        |       01 | T           |
| Metabolism and nutrition disorders | Hypertriglycerida emia             | N         | Moderat e    | Possible        |       03 | T           |

No deaths or other serious adverse events occurred over the course of the study.

No adverse events were determined by the PI to have impacted subject safety or clinical data reliability/integrity.

The incidence of the AE was higher after administration of the Test (8 AE) compared to the Reference products (4AE). No SAE were reported. There were 2 moderate AE, reported after administration of the Test product. However, overall, Emtricitabine, Rilpivirine and Tenofovir Alafenamide Tablets 200 mg/25 mg/ 25 mg was well tolerated as a single, oral 200 mg/25 mg/ 25 mg (1 x 200 mg/25 mg/ 25 mg) dose administered under fed conditions.

## 2.3.2.1.1. Pharmacokinetic Conclusion

Based on the presented bioequivalence study EMRTA-TFZ-1003 Emtricitabine, Rilpivirine, Tenofovir Alafenamide Viatris 200/25/25 mg film-coated tablets can be considered bioequivalent with Odefsey 200 mg/25 mg/25 mg.

## 2.3.2.2. Pharmacodynamics

No new pharmacodynamic studies were presented and no such studies are required for this application.

## 2.3.3. Discussion on clinical pharmacology

To support this MAA single pivotal study EMRTA-TFZ-1003 evaluate the bioequivalence of  test product (emtricitabine, rilpivirine, tenofovir alafenamide 200/25/25 mg film-coated tablets) with the reference product Odefsey 200 mg/25 mg/25 mg (emtricitabine, rilpivirine, tenofovir alafenamide) film-coated tablets under fed conditions was conducted.

The overall design of the study (open labelled, single-dose, randomised, two treatment, four period, two-sequence, fully replicate crossover study) is considered adequate. The wash-out periods of 28 days between Period I and Period II and 10 days between Period II and Period III and Period III and Period IV, taking into account that no pre-dose levels have been detected. Choice of the dose,

<div style=\"page-break-after: always\"></div>

sampling time points, overall sampling time appear reasonable. The choice of the EU reference product, sourced from the Netherlands is appropriate.

The samples collection times appear adequate. Pharmacokinetic variables are considered acceptable.

54 subjects checked into the clinical facility for Period 1, Period 2 and Period 3. 52 subjects were checked into the clinical facility for Period 4. In total 3 subjects were discontinued by the Investigator and 1 subject withdrew consent. 54 subjects were included for pharmacokinetic and statistical analysis of Emtricitabine, Rilpivirine, Tenofovir Alafenamide and Tenofovir. This is in line with CPMP/EWP/QWP/1401/98 Rev. 1/ Corr ** that states that only subjects in a crossover trial who do not provide evaluable data for both of the test and reference products should not be included in the statistical analysis.

90% confidence intervals were within the acceptable bioequivalent range of 80.00% and 125.00% for Cmax and AUC0-inf of emtricitabine.

90% confidence intervals were within the acceptable bioequivalent range of 80.00% and 125.00% for AUC0-t of Emtricitabine and tenofovir alafenamide.

90% confidence intervals were within the acceptable bioequivalent range of 80.00% and 125.00% for Cmax and AUC0-72 of rilpivirine.

Since the intrasubject variability of reference for Tenofovir Alafenamide was 37.89% for Cmax, bioequivalence was assessed using the scaled average bioequivalence approach. The calculated 90% confidence intervals (85.05% and 99.44%) of Tenofovir Alafenamide were within the acceptance limits of 75.70% to 132.10%. However, since 90% CI for Cmax were within conventional criteria, widening of acceptance criteria for Cmax was not needed.

It should be noted that BE is based on parent drug tenofovir alafenamide and that tenofovir data are considered supportive.

In total 12 TEAEs were reported by 9 subjects during the Study. The incidence of the AE was higher after administration of the Test (8 AE) compared to the Reference products (4AE). No SAE were reported. There were 2 moderate AE, reported after administration of the Test product. However, overall, Emtricitabine, Rilpivirine and Tenofovir Alafenamide Tablets 200 mg/25 mg/ 25 mg was well tolerated as a single, oral 200 mg/25 mg/ 25 mg (1 x 200 mg/25 mg/ 25 mg) dose administered under fed conditions.

Based on the results of the Study EMRTA-TFZ-1003  Emtricitabine, Rilpivirine and Tenofovir Alafenamide Tablets 200 mg/25 mg/ 25 mg can be considered bioequivalent to Gilead Sciences Ireland's Odefsey 200 mg/25 mg/25 mg film coated tablets Emtricitabine/Rilpivirine/Tenofovir alafenamide following a single, oral 200 mg/25 mg/ 25 mg (1 x 200 mg/25 mg/ 25 mg) dose administered under fed conditions.

In line with CPMP/EWP/QWP/1401/98 Rev. 1/ Corr ** recommendations, for products where the SmPC recommends intake of the reference medicinal product only in fed state, the bioequivalence study should generally be conducted under fed conditions. The finished product is presented as immediate release, film-coated tablets. Therefore, the bioequivalence study under fasting conditions is not considered necessary to support this MAA.

Comparative in vitro dissolution study comparing dissolution profiles of the test product Emtricitabine, Rilpivirine and Tenofovir Alafenamide 200 mg/25 mg/25 mg film-coated tablets and EU reference product Odefsey 200 mg/25 mg/25 mg film-coated tablets was performed in different dissolution

<div style=\"page-break-after: always\"></div>

media in line with the CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **. 12 units of the product for each experiment was used, which is supported.

The applicant has generated additional dissolution profile data by using 50 rpm with Paddle apparatus for the test product and EU reference product Odefsey 200 mg/25 mg/25 mg film-coated tablets (MAH: Gilead Sciences Ireland UC) in different dissolution media and results are presented below. However, the provided results did not demonstrate that the dissolution profiles are similar. In pH 0.1 N Hydrochloric acid for emtricitabine and tenofovir alafenamide, in pH 4.5 and in pH 6.8 for rilpivirine dissolution similarity has not been demonstrated.

In line with the CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **: 'In the event that the results of comparative in vitro dissolution of the biobatches do not reflect bioequivalence as demonstrated in vivo the latter prevails. However, possible reasons for the discrepancy should be addressed and justified'.

The applicant justified that differences in dissolution profiles are caused by differences in qualitative compositions of both the Test and Reference product.

## 2.3.3.1. Post-marketing experience

No post-marketing data are available. The medicinal product has not been marketed in any country.

## 2.3.4. Conclusions on clinical aspects

Based on the presented bioequivalence study EMRTA-TFZ-1003, Emtricitabine/Rilpivirine/ Tenofovir Alafenamide Viatris 200/25/25 mg film-coated tablets can be considered bioequivalent to Odefsey 200 mg/25 mg/25 mg.

## 2.4. Risk Management Plan

## 2.4.1. Safety concerns

| Important Identified Risks   | • None                                                                            |
|------------------------------|-----------------------------------------------------------------------------------|
| Important Potential Risks    | • None                                                                            |
| Missing Information          | • Long-term safety information in adolescents • Safety in Pregnancy and Lactation |

## 2.4.2. Pharmacovigilance plan

| Study & Status                                                | Summary of Objectives                                                                                | Safety Concerns Addressed                                     | Milestones                                                    | Due Dates                                                           |
|---------------------------------------------------------------|------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------------|
| Category 3 - Required Additional Pharmacovigilance Activities | Category 3 - Required Additional Pharmacovigilance Activities                                        | Category 3 - Required Additional Pharmacovigilance Activities | Category 3 - Required Additional Pharmacovigilance Activities | Category 3 - Required Additional Pharmacovigilance Activities       |
| Antiretroviral Pregnancy Registry On-going                    | To collect information on the risk of birth defects in patients exposed to Emtricitabine/Rilpivirine | - Missing information: Safety in pregnancy                    | Interim reports Final Report                                  | Semi-annual When 1000 first trimester exposures each antiretroviral |

<div style=\"page-break-after: always\"></div>

| /Tenofovir Alafenamide during pregnancy   | therapy is attained or when a subsequent mechanism for monitoring pregnancy outcomes emerges (e.g., standardized national monitoring program).   |
|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|

## 2.4.3. Risk minimisation measures

| Safety Concern                                                   | Risk Minimisation Measures                                                                                    | Pharmacovigilance Activities                                                                                                                                                       |
|------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing information: Long-term safety information in adolescents | Routine risk minimization measures: None Additional risk minimisation measures: None                          | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None                                                                                  |
| Missing information: Safety in Pregnancy and Lactation           | Routine risk minimization measures: SmPC section 4.6 PL section 2 Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: Antiretroviral Pregnancy Registry (APR) |

## 2.4.4. Conclusion

The CHMP and PRAC considered that the risk management plan version 0.3 is acceptable.

## 2.5. Pharmacovigilance

## 2.5.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.5.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.6. Product information

## 2.6.1. User consultation

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to Odefsey 200 mg/ 25 mg/ 25 mg film-coated tablets (EMEA/H/C/004156) and Abevmy 25 mg/ml concentrate for solution for infusion (EMEA/H/C/005327). The bridging report submitted by the applicant has been found acceptable.

## 3. Benefit-risk balance

This application concerns a generic version of Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) 200/25/25 mg film-coated tablets. The reference product Odefsey is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated with resistance to the nonnucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤ 10 0,000 HIV-1 RNA copies/mL.

No non-clinical studies have been provided for this application but an adequate summary of the available non-clinical information for the active substance was presented and considered sufficient. From a clinical perspective, this application does not contain new data on the pharmacokinetics and pharmacodynamics as well as the efficacy and safety of the active substance; the applicant's clinical overview on these clinical aspects based on information from published literature is considered sufficient.

The bioequivalence study EMRTA-TFZ-1003 forms the pivotal basis with an open labelled, single-dose, randomised, two-treatment, four-period, two-sequence, fully replicate crossover study design. The study design is considered adequate to evaluate the bioequivalence of this formulation and was in line with the respective European requirements. The wash-out periods of 28 days between Period I and Period II and 10 days between Period II and Period III and Period III and Period IV, taking into account that no pre-dose levels have been detected. Choice of the dose, sampling time points, overall sampling time appear reasonable. The choice of the EU reference product, sourced from the Netherlands is appropriate. The analytical method was validated. Pharmacokinetic and statistical methods applied are adequate.

The test formulation (emtricitabine, rilpivirine, tenofovir alafenamide 200/25/25 mg film-coated tablets) met the protocol-defined criteria for bioequivalence when compared with the Odefsey 200 mg/25 mg/25 mg (emtricitabine, rilpivirine, tenofovir alafenamide) film-coated tablets.

90% confidence intervals were within the acceptable bioequivalent range of 80.00% and 125.00% for Cmax and AUC0-inf of emtricitabine. 90% confidence intervals were within the acceptable bioequivalent range of 80.00% and 125.00% for AUC0-t of emtricitabine and tenofovir alafenamide. 90% confidence intervals were within the acceptable bioequivalent range of 80.00% and 125.00% for Cmax and AUC0-72 of rilpivirine. Since the intrasubject variability of reference for tenofovir alafenamide was 37.89% for Cmax, bioequivalence was assessed using the scaled average bioequivalence approach. The calculated 90% confidence intervals (85.05% and 99.44%) of tenofovir alafenamide were within the acceptance limits of 75.70% to 132.10%. However, since 90% CI for Cmax were within conventional criteria, widening of acceptance criteria for Cmax was not needed.

It should be noted that bioequivalence is based on parent drug tenofovir alafenamide and that tenofovir data are considered supportive.

<div style=\"page-break-after: always\"></div>

A benefit-risk ratio comparable to the reference product can therefore be concluded from a clinical perspective.

Having considered the data submitted in the application and available on the chosen reference medicinal product, no additional risk minimisation activities are required beyond those included in the product information.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris is favourable in the following indication:

Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated with resistance to the nonnucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤ 100 000 HIV-1 RNA copies/mL (see sections 4.2, 4.4 and 5.1).

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## · Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

These conditions fully reflect the advice received from the PRAC.